Little Green Pharma Limited

Psilocybin And MDMA Down- Scheduled

LGP’s psychedelics subsidiary Reset Mind Sciences welcomes the TGA’s decision to down-schedule psilocybin and MDMA

Little Green Pharma (ASX: LGP) and its psychedelics focused subsidiary Reset Mind Sciences Limited (“Reset Mind Sciences”) welcome Friday’s decision by the Therapeutic Goods Administration (“TGA”) to change the classification of psilocybin and MDMA to allow prescribing by authorised psychiatrists.


A copy of the media release is available here: https://www.tga.gov.au/news/media-releases/change- classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists

The announcement means Australia will become the first market in the world to recognise psychedelics as medicines and paves the way for the use of psilocybin for the treatment of treatment resistant depression and MDMA for PTSD outside of a clinical trial environment from 1 July 2023.

The TGA’s decision to re-classify psilocybin and MDMA has come significantly earlier than expected by industry, given the TGA’s decision in late December 2021 not to reclassify and limit use to clinical trials only. However, the unexpected change uniquely positions Reset compared to other psychedelic companies in Australia given both its Schedule 9 licence, authorizing it to cultivate and supply psilocybin, and its impending clinical trial, enabling Reset to validate its treatment protocols for the use of psilocybin in connection with treatment resistant depression. These developments now allow Reset to accelerate and implement its commercialisation plans far earlier than expected.

Reset Mind Sciences CEO Mr. Shaun Duffy said, “The announcement by the TGA is truly ground- breaking in the field of psychedelics and I welcome their decision. There is a significant body of research emerging in Australia and globally for the use of psychedelics to treat mental health conditions and this decision allows the use of these drugs for the mental health conditions that have demonstrated the most potential in the research.”

Reset Mind Sciences is in the advanced stages of preparations for a Perth based clinical trial using psilocybin for treatment resistant depression, the condition the TGA has identified as permissible for treatment under its prescribed parameters.

Mr. Duffy said, ”We have put more than 18 months of detailed planning into our trial with a focus on testing, refining and developing the therapy protocols that go along with the administration of psilocybin. This is a specialised field of expertise in itself that should not be underestimated and our trial provides an environment to optimise our protocols. We have assembled an outstanding team of therapists that are trained and ready to go once we finalise the ethics approval process. Given the comments from the Ethics Committee to date we hope and expect that’s not far away.”

The trial’s Principal Investigator is the University of Western Australia’s Professor Sean Hood who will have oversight of responsible governance and treatment delivery.

Itisincumbenton the industry to proceed in a professional and responsible manner with this treatment and ensure those administering it have the necessary skills” added Mr Duffy.

In addition, Reset Mind Sciences is in the final stages of commissioning construction of a bespoke mushroom cultivation facility which is expected to be on site at LGP’s existing cannabis cultivation facility in the coming weeks. Reset is one of a very limited number of Australian companies legally permitted to cultivate psilocybin containing mushrooms. Reset’s objective is to be able to produce GMP grade psilocybin from its mushrooms as soon as possible.

Mr. Duffy added, “Reset is fortunate that its clinical trial indication focus on treatment resistant depression matches the TGA’s psilocybin policy, as well as deciding to obtain a Schedule 9 supply and manufacturing licence in 2019 to enable progress of its inhouse psilocybin production capability. We believe the advanced stage of Reset’s treatment ecosystem puts the company in a strong leadership position for this significant therapeutic development.

We’re still working through the full implications of the TGA’s decision for our strategy moving forward but suffice to say it’s a very positive development for us and will result in an acceleration of our plans.”

Little Green Pharma has previously announced its intention to demerge Reset by way of an in- specie distribution of its current ownership out to its shareholder base. If approved by LGP shareholders, the effect would be that eligible LGP shareholders on a certain record date (to be determined) would receive a separate direct shareholding in Reset Mind Sciences and the opportunity to invest additional funds into it.

Given this regulatory development and that Reset is on the precipiceof becoming operational on both the clinical trial and cultivation fronts, we believe the time is right to move ahead with the demerger of Reset Mind Sciences from Little Green Pharma into a standalone dedicated psychedelics company.”


Click here for the full ASX Release

This article includes content from Little Green Pharma, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Charts and pen on desk, Tilray Brands logo.

Cannabis Round-Up: Tilray Reports Quarterly Results, Nebraska Adjusts Proposed CBD Tax Rate

Major cannabis industry player Tilray Brands (TSX:TLRY,NASDAQ:TLRY) disappointed investors with its latest quarterly results this week, falling short of analysts' expectations in the wake of a number of acquisitions.

Meanwhile, Nebraska lawmakers have proposed a lower tax rate for CBD after their initial offer was criticized, and unionized cannabis workers are preparing to strike on 4/20 as they seek improved benefits.

Stay up to date on the latest news, trends and policy developments in the cannabis industry with our round-up below.

Keep reading...Show less

Trulieve Cannabis Corp. to Hold First Quarter 2024 Results Conference Call on May 9, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Thursday, May 9, 2024 at 8:30 AM Eastern Time following the release of its first quarter 2024 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830

Passcode:

3368806

International: 1-412-542-4136

Passcode:

3368806

A live audio webcast of the conference call will be available at:
https://app.webinar.net/gl7Pnd4n40e

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-first-quarter-2024-results-conference-call-on-may-9-2024-302108647.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/05/c4744.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces April 2024 Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation in April.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

  • Benzinga Cannabis Capital Conference, Miami, Florida : Founder and CEO Kim Rivers will participate in a panel discussion at 1 pm eastern on April 17 th with the Bellamy Brothers, campaign spokesmen for the Smart & Safe Florida initiative.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-april-2024-event-participation-302107164.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/03/c8191.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

CORRECTION - ACE Venture Enterprises, Inc. Announces Planned Acquisition of Vireo Health of New York from Goodness Growth Holdings

Led by Steven Acevedo and Art Isagholian, ACE Venture Enterprises, Inc., a minority-owned business, plans to acquire Vireo Health of New York to accelerate entry into the New York market –

– Ace plans to retain Goodness Growth with a collaborative advisory agreement to advance the long-term success of both organizations –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings Announces Fourth Quarter and Full Year 2023 Results

Company demonstrates improved performance with record revenue and operating income in fiscal year 2023 –

– Q4 2023 revenue of $24.2 million excluding discontinued operations increased 34.4% year-over-year –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Applauds Florida Supreme Court for Affirmative Ruling on the Smart & Safe Florida Ballot Initiative

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., applauds the Florida Supreme Court for ruling affirmatively on the Smart & Safe Florida initiative and placing it on the 2024 General Election ballot. The initiative, if passed, will allow adults over the age of 21 to purchase cannabis products for personal consumption.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

"We are thankful that the Court has correctly ruled the ballot initiative and summary language meets the standards for single subject and clarity. We look forward to supporting this campaign as it heads to the ballot this Fall," said Trulieve CEO Kim Rivers .

Rivers added, "Trulieve was the primary financial supporter of the initiative during the signature gathering effort and subsequent court challenge and is a proud supporter, alongside a strong coalition of other companies, of the next important phase to educate Floridians on the amendment and secure a yes vote on Amendment 3 this November."

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-applauds-florida-supreme-court-for-affirmative-ruling-on-the-smart--safe-florida-ballot-initiative-302104809.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/01/c4879.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×